Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Not yet recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 12Thoracic 6Sarcoma 3Gastrointestinal 3Breast 3Tumor-Agnostic 2Genitourinary 2Dermatologic 2Other hematologic neoplasm 1Myeloid 1

Conditions

Neurofibrosarcoma 3Neurofibromatosis 1 3Sarcoma 1

Interventions

Cyclophosphamide 54Specimen Handling 50Magnetic Resonance Spectroscopy 49pembrolizumab 43Doxorubicin 43Radiotherapy 42Temozolomide 37Biopsy 34Radiation 29Nivolumab 28fludarabine 23Vincristine 22Irinotecan 21Gemcitabine 21X-Rays 20Surgical Procedures, Operative 19Ifosfamide 19atezolizumab 17cabozantinib 15Ipilimumab 15olaparib 13Sunitinib 13Paclitaxel 13regorafenib 12fludarabine phosphate 12Phantoms, Imaging 12Imatinib Mesylate 12Etoposide 12Blood Specimen Collection 12Carboplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
AZD 6244 × Sarcoma × 1 year × Clear all
NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
21 enrolled 12 charts
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

University of Alabama at Birmingham

Phase 2 Not yet recruiting
41 enrolled
CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT06735820 2025-07-03

MEKMDM2

Children's National Research Institute

Phase 1/2 Not yet recruiting
45 enrolled
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡